Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06952517 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea
A Phase 2 study of Papulopustular Rosacea and Papular-pustular Rosacea, sponsored by Narrows Institute for Biomedical Research.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT06952517: Recruiting Phase 2 study of Papulopustular Rosacea and Papular-pustular Rosacea, sponsored by Narrows Institute for Biomedical Research.
NCT06952517 is a Phase 2 study of Papulopustular Rosacea and Papular-pustular Rosacea that is actively recruiting participants, run by Narrows Institute for Biomedical Research. The registered enrollment target is 20 participants, below the 278-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (93% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06952517, a Phase 2 study of Papulopustular Rosacea and Papular-pustular Rosacea, is actively recruiting participants, sponsored by Narrows Institute for Biomedical Research.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
Primary Outcome
We will perform both a paired and pooled statistical analysis. We will conduct a power analysis to determine statistical significance. For the paired analysis, we will calculate the average gland size per patient at baseline and again at the end of the treatment period from all the individual's biopsy sites. We will then calculate the percent reduction of sebaceous gland size between the two average sizes. Finally, we will calculate the average percent change across all participants. For the po
Conditions Studied
Interventions
- DRUG Clascoterone Cream 1%
Study Locations (1)
New York
- New York Harbor VA Brooklyn Campus - Brooklyn
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2025-03-14 |
| Est. Completion | 2025-09-30 |
| Phase | Phase 2 |
What NCT06952517 shows while recruiting
NCT06952517 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 278-participant average among 11 other Papulopustular Rosacea trials with a reported enrollment target (93% lower).
The record links to 3 conditions, with Papulopustular Rosacea appearing as the primary indexed condition, and to 1 intervention - of which Clascoterone Cream 1% is the first listed.
NCT06952517 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT06952517 about?
NCT06952517 is a clinical study titled "Efficacy and Safety of Topical Clascoterone (WINLEVI) Cream 1% in Patients With Facial Acneiform Rosacea". To demonstrate the efficacy of Clascoterone cream 1% in reducing the size of sebaceous glands in study participants with acneiform rosacea.
What is the current status of trial NCT06952517?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 20 participants. The study started on 2025-03-14. Estimated completion is 2025-09-30.
What conditions does trial NCT06952517 study?
This clinical trial studies the following conditions: Papulopustular Rosacea, Papular-pustular Rosacea, Papulopustular Rosacea (PPR).
What interventions are being tested in trial NCT06952517?
The interventions under investigation include: Clascoterone Cream 1% (DRUG).
Who is sponsoring clinical trial NCT06952517?
This trial is sponsored by Narrows Institute for Biomedical Research, which has 5 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06952517 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Papulopustular Rosacea
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06952517's enrollment target sits among peer trials
20 11th of 11 higher than 1 of 11 other Papulopustular Rosacea trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Papulopustular Rosacea trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Twelve Week Safety and Efficacy Study in Rosacea
COMPLETED · Phase 2
-
Safety, Efficacy and Pharmacokinetics of Rifaximin in Patients With Moderate-to-severe Papulopustular Rosacea
COMPLETED · Phase 2
-
Evaluation of Topical Encapsulated Benzoyl Peroxide on the Skin Microbiome and Skin Biophysical Properties
COMPLETED · Phase 1
-
A Therapeutic Equivalence Study of Two Metronidazole Gel 1% Topical Treatments of Rosacea
COMPLETED · Phase 3
-
Excel V 532 nm KTP Laser for Treatment of Erythematotelangiectatic Rosacea & Papulopustular Rosacea
COMPLETED · NA
-
Patient Centered Outcomes in Rosacea: An Exploratory Multi-media Analysis of the Patient Experience on Oracea
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI